Form 4: Travere Therapeutics Officer Sells Shares
Insider Transaction Report
Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 2,910 shares of common stock for $36 per share under a pre-arranged trading plan.
Summary
- Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, Inc. (TVTX), reported the sale of 2,910 shares of common stock.
- The transaction occurred on December 15, 2025, at a price of $36 per share.
- The total value of the shares sold was $104,760.
- Following this transaction, Ms. Calvin beneficially owns 45,635 shares of common stock.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on June 10, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine disclosure of an insider stock sale conducted under a pre-arranged 10b5-1 plan, which typically does not indicate new material information or a change in company fundamentals.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, adopted on June 10, 2025, indicating a pre-scheduled transaction rather than one based on new, non-public information.
Negatives
- An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction report is specific to Travere Therapeutics and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. This demonstrates adherence to best practices for insider trading compliance, ensuring transactions are pre-scheduled and not based on material non-public information. | 06/10/2025 | Enhances transparency and mitigates concerns regarding potential misuse of insider information, reinforcing investor confidence in corporate governance practices. |
Stakeholder Impact
- Shareholders: May observe a slight reduction in insider ownership, though mitigated by the pre-planned nature of the sale under a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date Rule 10b5-1 trading plan was adopted. |
| 12/15/2025 | Date of common stock transaction (sale). |
| 12/16/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe reported transaction is a pre-planned sale by an executive under a Rule 10b5-1 plan. Such routine insider sales are generally not indicative of new material information about the company's prospects and typically do not warrant a change in investment recommendation. The sale volume is not exceptionally large relative to the company's market capitalization or the executive's overall holdings to suggest a significant shift in sentiment.
Keywords
Travere Therapeutics, TVTX, insider trading, Form 4, stock sale, Sandra Calvin, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.